- Home
- BRBR vs AVTX Comparison
BRBR vs AVTX Comparison
Compare BRBR & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRBR | AVTX |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 888.6M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BRBR | AVTX |
|---|---|---|
| Price | $7.61 | $15.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 8 |
| Target Price | $36.63 | ★ $40.57 |
| AVG Volume (30 Days) | ★ 2.8M | 953.5K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $2,316,600,000.00 | $27,813,137.00 |
| Revenue This Year | $6.28 | N/A |
| Revenue Next Year | $5.81 | N/A |
| P/E Ratio | $8.15 | ★ N/A |
| Revenue Growth | 16.05 | ★ 2312.27 |
| 52 Week Low | $7.59 | $12.41 |
| 52 Week High | $36.95 | $24.27 |
Technical Indicators
Market Signals| Indicator | BRBR | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 23.55 | 33.84 |
| Support Level | N/A | $12.98 |
| Resistance Level | $9.42 | $15.27 |
| Average True Range (ATR) | 0.38 | 0.89 |
| MACD | -0.11 | -0.15 |
| Stochastic Oscillator | 2.50 | 16.32 |
Price Performance
Historical ComparisonAbout BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channel including club, food, drug and mass, eCommerce, convenience and specialty.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.